**Source:** Jumeili (聚美丽) · **Date:** 2026-10-13 · **Category:** Legal / Brand ownership *原文：“修丽可竞对”被强执1807万！* Obagi — the US clinical skincare brand Jumeili positions as a SkinCeuticals rival — is running on two very different tracks. Globally, British private-equity firm Bridgepoint has taken over the brand's assets for up to $460 million (about ¥3.08bn), its second change of ownership in 2026. In China the picture is less flattering: the brand's local operating entity has been hit with a fresh compulsory enforcement order of ¥18.07m, the latest in a series of legal and commercial setbacks for the mainland business. Jumeili reads Obagi as the archetype of the 'efficacy skincare meets light medical aesthetics' (妆械联合) thesis that has capital re-rating brands with both retail credibility and clinic-channel presence. The divergence — a premium global price tag and an enforcement notice at home — is a caution on how unevenly that thesis lands across markets. Detail --- Bridgepoint (UK private equity) ¥18.07m compulsory enforcement order SkinCeuticals rival; efficacy skincare + clinics Oct 13, 2026, Jumeili [Read the original article](https://www.jumeili.cn/news/view/48158.html)

相关内容